142 related articles for article (PubMed ID: 9132317)
21. Paradoxical reaction of raynaud phenomenon following the repeated administration of iloprost in a patient with diffuse cutaneous systemic sclerosis.
Barreira RI; García BB; López MG; Legazpi IR; Díaz HÁ; Penín IR
Ann Pharmacother; 2012 Oct; 46(10):e28. PubMed ID: 23032649
[TBL] [Abstract][Full Text] [Related]
22. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.
Wigley FM; Wise RA; Seibold JR; McCloskey DA; Kujala G; Medsger TA; Steen VD; Varga J; Jimenez S; Mayes M; Clements PJ; Weiner SR; Porter J; Ellman M; Wise C; Kaufman LD; Williams J; Dole W
Ann Intern Med; 1994 Feb; 120(3):199-206. PubMed ID: 7506013
[TBL] [Abstract][Full Text] [Related]
23. Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis.
Zachariae H; Halkier-Sørensen L; Bjerring P; Heickendorff L
Acta Derm Venereol; 1996 May; 76(3):236-8. PubMed ID: 8800308
[TBL] [Abstract][Full Text] [Related]
24. Possible role of iloprost (stable analog of PG12) in promoting neoangiogenesis in systemic sclerosis.
Faggioli P; Giani L; Mazzone A
Clin Exp Rheumatol; 2006; 24(2):220-1. PubMed ID: 16762173
[No Abstract] [Full Text] [Related]
25. Exhaled nitric oxide and pulmonary response to iloprost in systemic sclerosis with pulmonary hypertension.
Rolla G; Colagrande P; Brussino L; Bucca C; Bertero MT; Caligaris-Cappio F
Lancet; 1998 May; 351(9114):1491-2. PubMed ID: 9605813
[No Abstract] [Full Text] [Related]
26. [Iloprost for the treatment of systemic sclerosis].
Hachulla E; Launay D; Hatron PY
Presse Med; 2008 May; 37(5 Pt 2):831-9. PubMed ID: 18035518
[TBL] [Abstract][Full Text] [Related]
27. Inhaled iloprost for the treatment of Raynaud's phenomenon.
Pakozdi A; Howell K; Wilson H; Fox S; Gonzalez L; Black CM; Denton CP
Clin Exp Rheumatol; 2008; 26(4):709. PubMed ID: 18799113
[No Abstract] [Full Text] [Related]
28. Sustained success of therapy with inhaled iloprost for severe pulmonary arterial hypertension associated with systemic sclerosis and pulmonary fibrosis.
Ahmadi-Simab K; Köhler A; Gross WL
Clin Exp Rheumatol; 2007; 25(5):760-2. PubMed ID: 18078629
[TBL] [Abstract][Full Text] [Related]
29. Evidence for increase in finger blood flow, evaluated by laser Doppler flowmetry, following iloprost infusion in patients with systemic sclerosis: a week-long observational longitudinal study.
Rotondo C; Nivuori M; Chialà A; Praino E; Matucci Cerinic M; Cutolo M; Lapadula G; Iannone F
Scand J Rheumatol; 2018 Jul; 47(4):311-318. PubMed ID: 29409385
[TBL] [Abstract][Full Text] [Related]
30. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
[TBL] [Abstract][Full Text] [Related]
31. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].
Cordioli E; Virgilio S; Ghirardi R; Martinelli M
Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297
[TBL] [Abstract][Full Text] [Related]
32. Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease.
Hallioglu O; Dilber E; Celiker A
Am J Cardiol; 2003 Oct; 92(8):1007-9. PubMed ID: 14556887
[TBL] [Abstract][Full Text] [Related]
33. Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels.
Mittag M; Beckheinrich P; Haustein UF
Acta Derm Venereol; 2001; 81(4):294-7. PubMed ID: 11720181
[TBL] [Abstract][Full Text] [Related]
34. Long-term evaluation of lung function in patients affected by scleroderma treated with cyclic iloprost infusions.
Caramaschi P; Biasi D; Ferrari M; Volpe A; Martinelli N; Carletto A; Dal Forno P; Bambara LM
Rheumatol Int; 2005 May; 25(4):250-4. PubMed ID: 14963694
[TBL] [Abstract][Full Text] [Related]
35. The effects of iloprost infusion on microcirculation is independent of nitric oxide metabolites and endothelin-1 in chronic peripheral ischaemia.
Mazzone A; Cusa C; Bucci L; Vezzoli M; Ghio S; Buggia I; Regazzi MB; Fossati G; Mazzucchelli I; Gritti D
Eur J Clin Invest; 1999 Jan; 29(1):1-5. PubMed ID: 10092981
[TBL] [Abstract][Full Text] [Related]
36. A novel iloprost administration method with portable syringe pump for the treatment of acral ulcers and Raynaud's phenomenon in systemic sclerosis patients. A pilot study (ILOPORTA).
Fraticelli P; Martino GP; Murri M; Mattioli M; Gabrielli A
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):173-178. PubMed ID: 28869415
[TBL] [Abstract][Full Text] [Related]
37. Coagulative modifications in patients with systemic sclerosis treated with iloprost or nifedipine.
Candela M; Pansoni A; Jannino L; Menditto VG; Natalini M; Ravaglia F; Da Lio L; Scorza R; Gabrielli A; Danieli G
Ann Ital Med Int; 2001; 16(3):170-4. PubMed ID: 11692906
[TBL] [Abstract][Full Text] [Related]
38. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
Black CM; Halkier-Sørensen L; Belch JJ; Ullman S; Madhok R; Smit AJ; Banga JD; Watson HR
Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
[TBL] [Abstract][Full Text] [Related]
39. Iloprost infusion reduces serological cytokines and hormones of hypoxia and inflammation in systemic sclerosis patients.
Pellicano C; Colalillo A; De Marco O; Carnazzo V; Basile U; Gigante A; Cianci R; Rosato E
Clin Exp Med; 2024 May; 24(1):109. PubMed ID: 38777916
[TBL] [Abstract][Full Text] [Related]
40. Intravenous iloprost for pulmonary arterial hypertension: still waiting for evidence.
Provencher S; Sitbon O
Eur Respir J; 2009 Jul; 34(1):7-9. PubMed ID: 19567597
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
